Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY LUTS: Lower Urinary Tract Symptoms Pub Date : 2024-10-10 DOI:10.1111/luts.12534

Yoshikazu Togo, Yohei Kaizuka, Seiji Nagasawa, Keisuke Kajio, Nobuyuki Kondoh, Keizo Taguchi

{"title":"Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study","authors":"Yoshikazu Togo, Yohei Kaizuka, Seiji Nagasawa, Keisuke Kajio, Nobuyuki Kondoh, Keizo Taguchi","doi":"10.1111/luts.12534","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Nocturia is considered a clinical problem when nocturnal urinary frequency is two or more times. For affected patients, development of depression, falling, and increased mortality rate are matters of concern. The present study investigated the efficacy and safety of lemborexant for insomnia patients with nocturia.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Insomnia patients (Athens Insomnia Scale [AIS] ≥ 6) who typically awoke twice or more during the night to urinate and were examined at our institutions from June 2021 to December 2022 were enrolled. Each was administrated 5 mg of lemborexant, one tablet, daily for 4 weeks. Total AIS score, nocturia frequency, individual frequency-volume chart findings, and N-QOL score were examined before and after administration.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of the 37 patients recruited, 5 were excluded, thus 32 were enrolled and subjected to analyses. Following lemborexant therapy, the mean AIS total score was significantly decreased from 11.4 to 7.8 (<i>p</i> < 0.01) as was mean number of nocturia episodes from 3.4 to 2.3 (<i>p</i> < 0.001). Furthermore, the mean single voided urine volume at night was significantly increased from 182.5 to 225.3 mL (<i>p</i> < 0.001)and mean period of undisturbed sleep was significantly extended from 105.3 to 174.8 min (<i>p</i> < 0.001), while mean total N-QOL score was significantly improved from 49.6% to 64.8% (<i>p</i> < 0.001). As for adverse events, mild somnolence was observed in three cases.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Lemborexant may be effective and safe for use in insomniac patients with nocturia.</p>\n </section>\n </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"16 6","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"LUTS: Lower Urinary Tract Symptoms","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/luts.12534","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Nocturia is considered a clinical problem when nocturnal urinary frequency is two or more times. For affected patients, development of depression, falling, and increased mortality rate are matters of concern. The present study investigated the efficacy and safety of lemborexant for insomnia patients with nocturia.

Methods

Insomnia patients (Athens Insomnia Scale [AIS] ≥ 6) who typically awoke twice or more during the night to urinate and were examined at our institutions from June 2021 to December 2022 were enrolled. Each was administrated 5 mg of lemborexant, one tablet, daily for 4 weeks. Total AIS score, nocturia frequency, individual frequency-volume chart findings, and N-QOL score were examined before and after administration.

Results

Of the 37 patients recruited, 5 were excluded, thus 32 were enrolled and subjected to analyses. Following lemborexant therapy, the mean AIS total score was significantly decreased from 11.4 to 7.8 (p < 0.01) as was mean number of nocturia episodes from 3.4 to 2.3 (p < 0.001). Furthermore, the mean single voided urine volume at night was significantly increased from 182.5 to 225.3 mL (p < 0.001)and mean period of undisturbed sleep was significantly extended from 105.3 to 174.8 min (p < 0.001), while mean total N-QOL score was significantly improved from 49.6% to 64.8% (p < 0.001). As for adverse events, mild somnolence was observed in three cases.

Conclusions

Lemborexant may be effective and safe for use in insomniac patients with nocturia.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伦博雷沙坦治疗夜尿失眠患者的疗效和安全性--一项前瞻性研究

目的：当夜尿次数达到 2 次或 2 次以上时，夜尿就被视为一种临床问题。对于夜尿症患者来说，抑郁、跌倒和死亡率的增加都是令人担忧的问题。本研究探讨了利眠宁对夜尿症失眠患者的疗效和安全性：方法：选取2021年6月至2022年12月在我院接受检查的失眠患者（雅典失眠量表[AIS]≥6）为研究对象，这些患者通常在夜间醒来两次或两次以上排尿。每人每天服用一片 5 毫克的利眠宁，连续服用 4 周。对用药前后的 AIS 总分、夜尿次数、单次尿量图表结果和 N-QOL 评分进行了检查：结果：在招募的 37 名患者中，有 5 人被排除在外，因此有 32 人被招募并接受了分析。经过伦博雷沙坦治疗后，AIS 总分的平均值从 11.4 显著下降至 7.8（p 结论：伦博雷沙坦可能是一种有效的治疗药物：对于有夜尿症的失眠患者来说，使用伦博雷沙坦可能既有效又安全。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

LUTS: Lower Urinary Tract Symptoms UROLOGY & NEPHROLOGY-

CiteScore

3.00

自引率

7.70%

发文量

审稿时长

>12 weeks

期刊介绍： LUTS is designed for the timely communication of peer-reviewed studies which provides new clinical and basic science information to physicians and researchers in the field of neurourology, urodynamics and urogynecology. Contributions are reviewed and selected by a group of distinguished referees from around the world, some of whom constitute the journal''s Editorial Board. The journal covers both basic and clinical research on lower urinary tract dysfunctions (LUTD), such as overactive bladder (OAB), detrusor underactivity, benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), urinary incontinence, pelvic organ prolapse (POP), painful bladder syndrome (PBS), as well as on other relevant conditions. Case reports are published only if new findings are provided. LUTS is an official journal of the Japanese Continence Society, the Korean Continence Society, and the Taiwanese Continence Society. Submission of papers from all countries are welcome. LUTS has been accepted into Science Citation Index Expanded (SCIE) with a 2011 Impact Factor.